EPISODE · Nov 12, 2015 · 5 MIN
Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?
from GRACEcast · host cancerGRACE Meetings
Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.
Embed this episode
NOW PLAYING
Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?
0:00
5:09
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
GRACEcast Radiation Oncology Video
cancerGRACE - H. Jack West, MD
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
cancerGRACE
In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership. We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis. For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums
GRACEcast Lung Cancer Audio
cancerGRACE - H. Jack West, MD
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
GRACEcast Lung Cancer Video
cancerGRACE - H. Jack West, MD
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Frequently Asked Questions
How long is this episode of GRACEcast?
This episode is 5 minutes long.
When was this GRACEcast episode published?
This episode was published on November 12, 2015.
Can I download this GRACEcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!